Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современная тактика адъювантной лекарственной терапии больных операбельным (ранним) раком молочной железы
Современная тактика адъювантной лекарственной терапии больных операбельным (ранним) раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Goldhirsch A, Coates AS, Gelber RD et al. First sel ect the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17: 1772–6.
2. Dowsett M, ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen alone or in combination) trial according to esrtrogen receptor and progesterone receptor status. Breast Cancer Res Traet 2003; 82–7.
3. Osborne K. Endocrine Responsiveness: Understanding How Progesterone Receptor Can be used to Sel ect Endocrine Therapy. The Breast, Primary Therapy of Early Breast Cancer, 2005; 5.
4. Goss PE, Ingle JN, Matrino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793–802.
5. Burstein HJ, Punglia R. Choosing the Best Adjuvant Endocrine Treatment Strategy for Patients with Postmenopausal Breast Cancer: A Decision Analysis ASCO 2005 Educational Book, 40–44 ASCO 2005.
6. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes fr om adding sequential Paclitaxel but not fr om escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Onol 2003; 21 (6): 967–83.
7. Mackey J. The Role of Adjuvant Docetaxel in Early Stage Breast Cancer. ASCO 2005 Educational Book, 14–20 ASCO 2005.
8. Winer EP, Piccart-Gebhart MJ et al. Her 2-positive Breast Cancer in Current standards Practice and Future Directions Management of HER-Positive Breast Cancer. ASCO 2006 Educational Book, 3–15, 2006.
9. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334 (21): 1356–61.
10. van’T Veer LJ, Dae H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–6.
11. Perou CM. Therapeutic implication of the breast tumor intrinsic subtypes. The Breast 2007; 16 (suppl. 1): abs. S7, S2.
2. Dowsett M, ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen alone or in combination) trial according to esrtrogen receptor and progesterone receptor status. Breast Cancer Res Traet 2003; 82–7.
3. Osborne K. Endocrine Responsiveness: Understanding How Progesterone Receptor Can be used to Sel ect Endocrine Therapy. The Breast, Primary Therapy of Early Breast Cancer, 2005; 5.
4. Goss PE, Ingle JN, Matrino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793–802.
5. Burstein HJ, Punglia R. Choosing the Best Adjuvant Endocrine Treatment Strategy for Patients with Postmenopausal Breast Cancer: A Decision Analysis ASCO 2005 Educational Book, 40–44 ASCO 2005.
6. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes fr om adding sequential Paclitaxel but not fr om escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Onol 2003; 21 (6): 967–83.
7. Mackey J. The Role of Adjuvant Docetaxel in Early Stage Breast Cancer. ASCO 2005 Educational Book, 14–20 ASCO 2005.
8. Winer EP, Piccart-Gebhart MJ et al. Her 2-positive Breast Cancer in Current standards Practice and Future Directions Management of HER-Positive Breast Cancer. ASCO 2006 Educational Book, 3–15, 2006.
9. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334 (21): 1356–61.
10. van’T Veer LJ, Dae H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–6.
11. Perou CM. Therapeutic implication of the breast tumor intrinsic subtypes. The Breast 2007; 16 (suppl. 1): abs. S7, S2.
Авторы
Н.И.Переводчикова
Отделение химиотерапии НИИ клинической онкологии ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Отделение химиотерапии НИИ клинической онкологии ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.